Lung Transplant Rejection – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Lung Transplant Rejection – Pipeline Review, H2 2016’, provides an overview of the Lung Transplant Rejection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lung Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lung Transplant Rejection and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Lung Transplant Rejection

The report reviews pipeline therapeutics for Lung Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Lung Transplant Rejection therapeutics and enlists all their major and minor projects

The report assesses Lung Transplant Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Lung Transplant Rejection

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Lung Transplant Rejection

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Lung Transplant Rejection pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Apeptico Forschung und Entwicklung GmbH

Dompe Farmaceutici S.p.A.

Kamada Ltd.

Novartis AG

Proteo, Inc.

Quark Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Lung Transplant Rejection Overview 6

Therapeutics Development 7

Pipeline Products for Lung Transplant Rejection - Overview 7

Lung Transplant Rejection - Therapeutics under Development by Companies 8

Lung Transplant Rejection - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Lung Transplant Rejection - Products under Development by Companies 12

Lung Transplant Rejection - Companies Involved in Therapeutics Development 13

Apeptico Forschung und Entwicklung GmbH 13

Dompe Farmaceutici S.p.A. 14

Kamada Ltd. 15

Novartis AG 16

Proteo, Inc. 17

Quark Pharmaceuticals, Inc. 18

Lung Transplant Rejection - Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

alpha-1 proteinase inhibitor (human) - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

everolimus - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

FX-06 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

QPI-1024 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

QPLI-1 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

R-554 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

R-801 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

reparixin - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

solnatide - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

tiprelestat - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Lung Transplant Rejection - Dormant Projects 61

Lung Transplant Rejection - Product Development Milestones 62

Featured News & Press Releases 62

Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection 62

Dec 09, 2015: Quark announces issue of U.S. patent for novel treatment of lung transplantation associated injury 63

Jun 22, 2015: Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection 64

Mar 12, 2015: Elafin combined with cyclosporine promises to overcome limitations of cyclosporine for preventing irreversible damage to transplanted organs 65

Apr 17, 2013: APEPTICO initiates phase II clinical trial with AP301 in patients with primary graft dysfunction following lung transplantation 65

Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program 66

Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria 67

Appendix 68

Methodology 68

Coverage 68

Secondary Research 68

Primary Research 68

Expert Panel Validation 68

Contact Us 68

Disclaimer 69

List of Tables

List of Tables

Number of Products under Development for Lung Transplant Rejection, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Lung Transplant Rejection – Pipeline by Apeptico Forschung und Entwicklung GmbH, H2 2016 13

Lung Transplant Rejection – Pipeline by Dompe Farmaceutici S.p.A., H2 2016 14

Lung Transplant Rejection – Pipeline by Kamada Ltd., H2 2016 15

Lung Transplant Rejection – Pipeline by Novartis AG, H2 2016 16

Lung Transplant Rejection – Pipeline by Proteo, Inc., H2 2016 17

Lung Transplant Rejection – Pipeline by Quark Pharmaceuticals, Inc., H2 2016 18

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

Lung Transplant Rejection – Dormant Projects, H2 2016 61

List of Figures

List of Figures

Number of Products under Development for Lung Transplant Rejection, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy Products, H2 2016 19

Number of Products by Targets, H2 2016 20

Number of Products by Stage and Targets, H2 2016 20

Number of Products by Mechanism of Actions, H2 2016 22

Number of Products by Stage and Mechanism of Actions, H2 2016 22

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Types, H2 2016 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports